General Information of Drug (ID: DMJ83Z7)

Drug Name
CYT-609 Drug Info
Synonyms Aurimune
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMJ83Z7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug(s) Targeting Tumor necrosis factor (TNF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [3]
Nafamostat DMU1XOD Pancreatitis DC31-DC34 Approved [4]
Pentoxifylline DMU3DNC Alcoholic hepatitis DB94.1 Approved [5]
Lenalidomide DM6Q7U4 Adult T-cell leukemia/lymphoma Approved [6]
Enbrel DM7RNP3 Arthritis FA20 Approved [7]
Golimumab DMHZV7X Psoriatic arthritis FA21 Approved [8]
Certolizumab DM5CL9Z Rheumatoid arthritis FA20 Approved [9]
Etanercept DMCV109 Arthritis FA20 Approved [10]
Adalimumab DMQMV1B Crohn disease DD70 Approved [11]
Infliximab DMH7OIA Crohn disease DD70 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025369)
2 Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010 December 15; 16(24): 6139-6149.
3 Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
4 Clinical pipeline report, company report or official report of AstraZeneca (2009).
5 Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
6 Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
7 Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
8 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
9 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
10 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
11 Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
12 Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.